Abstract 271P
Background
To assess the cost-effectiveness of pembrolizumab monotherapy (P) for CPS ≥1 subpopulation and in combination with platinum+5-FU chemotherapy (P+C) for the overall population versus cetuximab+platinum+5-FU chemotherapy (EXTREME regimen: E) for the first line treatment of recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) in Taiwan.
Methods
A cohort-based partitioned survival model consisting of three health states (progression-free, progressed disease, and death) was developed. Using overall survival and progression free survival data from the P and P+C vs E arms of the KEYNOTE-048 study, the proportion of patients in each health state was estimated by parametric modeling over a 10-year period. Healthcare resource utilization data and costs per unit were sourced from the Taiwan National Healthcare Insurance Research Database, Cancer Registry database based on Taiwan National Health Insurance Administration (NHIA) reimbursement prices.
Results
In the base case analysis, P and P+C resulted in higher costs vs E (P: $1,964,859 vs E: $1,200,788 in the CPS ≥1 population; P+C: $2,301,474 vs E: $1,236,156 in the overall population), and higher quality adjusted life years (QALYs: P:1.22 vs 0.73 in the CPS ≥1 population; P+C: 1.30 vs 0.74 in the overall population). The incremental cost effectiveness ratio (ICER) for P vs E was NT$1,571,914/QALY in the CPS ≥1 population, and NT$1,912,195/QALY for P+C vs E in the overall population, respectively. At a willingness-to-pay threshold of 3 times Taiwan per capita Gross Domestic Product (GDP: NT$2,309,934), the resultant incremental cost/QALY for both P and P+C are considered cost-effective.
Conclusions
Both P and P+C are projected to be cost-effective options compared with E for the first-line treatment of R/M HNSCC patients. These results reflect the assumption of the publicly known pembrolizumab price in Taiwan; the price under managed entry agreement with NHIA may result in lower ICERs further demonstrating greater cost-effectiveness value.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
MSD LLC Taiwan Branch, Taiwan.
Funding
MSD LLC Taiwan Branch, Taiwan.
Disclosure
C.H. Wang: Advisory/Consultancy: Merck Sharp & Dohme (I.A.) LLC Taiwan Branch. All other authors have declared no conflicts of interest.
Resources from the same session
276P - Sarcopenia to predict overall survival in head and neck cancer patients receiving chemotherapy: A systematic review and meta-analysis
Presenter: Felix Kwenandar
Session: e-Poster Display Session
277P - Tegafur/uracil, platinum and cetuximab (UPEx) as first line treatment in frail patients with recurrent or metastatic head and neck squamous cell carcinoma
Presenter: Meng-che Hsieh
Session: e-Poster Display Session
278P - Serial assessment of parotid volume changes during radical chemoradiation of locally advanced head and neck cancer: Its implications in practice of adaptive radiotherapy
Presenter: Aathira T S
Session: e-Poster Display Session
279P - Clinico pathological characteristics and survival outcome in oral cavity cancer with masticator space involvement (T4b): A retrospective single institutional experience
Presenter: Abdulla Kunnummal Palathinkara
Session: e-Poster Display Session
280P - Safety and efficacy of concurrent chemoradiotherapy for head and neck cancers in younger versus older patients: Post hoc analysis of a randomized control trial
Presenter: Vanita Noronha
Session: e-Poster Display Session
281P - Prevalence of premalignant lesions and oral cancer among tobacco-using tea plantation workers of Nilgiri Hills, Tamilnadu, India
Presenter: Delfin Lovelina Francis
Session: e-Poster Display Session
282P - Filipino head and neck cancer patients and their quality of life
Presenter: Frederic Ivan Ting
Session: e-Poster Display Session
283P - Descriptive epidemiology of head and neck cancer in Niger: First results from the National Cancer Registry
Presenter: Salamatou Mamoudou Garba
Session: e-Poster Display Session
284P - Outcomes of metronomic adjuvant chemotherapy with tegafur-uracil in locally advanced head and neck squamous cell carcinoma
Presenter: Tsung-jang Yeh
Session: e-Poster Display Session
285P - Comparison of induction chemotherapy plus concurrent chemoradiotherapy and concurrent chemoradiotherapy alone in locally advanced nasopharyngeal carcinoma: A meta-analysis
Presenter: Xu Guoqiang
Session: e-Poster Display Session